Home Acta Virologica 2010 Acta Virologica Vol.54, No.3, p.155-163, 2010

Journal info

Founded: 1957
ISSN 0001-723X
E-ISSN 1336-2305

Published in English

Impact Factor = 1.82

Aims and Scope
Abstracted and Indexed

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Acta Virologica Vol.54, No.3, p.155-163, 2010

Title: Molecular characteristics of the human pandemic influenza A virus (H1N1)

Abstract: The outbreak of the human pandemic influenza A (H1N1) has caused a considerable public concern. The aim of this review was to improve our understanding of this novel virus by analyzing the relationships between its molecular characteristics and pathogenic properties. Results of this analysis indicate that the human pandemic influenza A (H1N1) virus is a new re-assorted virus, which combines genetic materials from the avian flu (H1N1) virus, classical swine flu (H1N1) virus, human flu (H3N2) virus, and Eurasian swine flu (H1N1) virus. Analysis of the sequences for receptor-binding and cleavage sites of hemagglutinin (HA), stalk region of neuraminidase (NA), non-structural protein 1 (NS1), polymerase basic protein 2 (PB2), and polymerase basic protein 1 (PB1) suggested that (i) the human pandemic influenza A (H1N1) virus is a low virulent and low pathogenic virus, (ii) its replication is restricted to the cells of upper respiratory tract, so it does not lead to a systemic infection, (iii) it spreads among humans only, (iv) its replication could be inhibited by oseltamivir, zanamivir, interferon (IFN), and tumor necrosis factor α (TNF-α). A potential application of amantadine might be complicated by the drug-resistant virus strains.

Keywords: molecular characteristics; pandemic; influenza A virus; H1N1
Year: 2010, Volume: 54, Issue: 3 Page From: 155, Page To: 163
Price: 21.60 €

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.